Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in COPD: A Randomized Trial.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC, Casaburi R, Tillmann HC, Lach-Trifilieff E, Roubenoff R, Rooks DS.

Am J Respir Crit Care Med. 2018 Aug 10. doi: 10.1164/rccm.201802-0286OC. [Epub ahead of print]

PMID:
30095981
2.

Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study.

Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, Make BJ, Crapo JD, DeMeo DL, Silverman EK; COPDGene Investigators .

Am J Respir Crit Care Med. 2018 Jun 6. doi: 10.1164/rccm.201804-0663OC. [Epub ahead of print]

PMID:
29874098
3.

Genetic variants predicting aerobic capacity response to training are also associated with skeletal muscle oxidative capacity in moderate-to-severe COPD.

Adami A, Hobbs BD, McDonald ML, Casaburi R, Rossiter HB; COPDGene Investigators.

Physiol Genomics. 2018 May 25. doi: 10.1152/physiolgenomics.00140.2017. [Epub ahead of print]

4.

Reliability and Physiological Interpretation of Pulmonary Gas Exchange by "Circulatory Equivalents" in Chronic Heart Failure.

Tan C, Rossiter HB, Porszasz J, Bowen TS, Witte KK, Stringer WW, Casaburi R, Hansen JE.

J Am Heart Assoc. 2018 Mar 27;7(7). pii: e008072. doi: 10.1161/JAHA.117.008072.

5.

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.

Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465818755091. doi: 10.1177/1753465818755091.

6.

Effect of tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1-2 COPD.

Porszasz J, Carraro N, Cao R, Gore A, Ma S, Jiang T, Maltais F, Ferguson GT, O'Donnell DE, Shaikh A, Rossiter HB, Casaburi R.

Respir Physiol Neurobiol. 2018 May;251:8-15. doi: 10.1016/j.resp.2018.02.006. Epub 2018 Feb 10.

PMID:
29438808
7.

Reply: Further Need for Evidence in Long-Term Oxygen Therapy.

Casaburi R.

Ann Am Thorac Soc. 2018 Apr;15(4):512-513. doi: 10.1513/AnnalsATS.201801-047LE. No abstract available.

PMID:
29384692
8.

Pulmonary rehabilitation relieves dyspnea, but does it reduce mortality?

Casaburi R.

Rev Med Suisse. 2018 Jan 24;14(591):176-177. No abstract available.

PMID:
29381274
9.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Spruit MA, Singh SJ, Rochester CL, Greening NJ, Franssen FME, Pitta F, Troosters T, Nolan C, Vogiatzis I, Clini EM, Man WD, Burtin C, Goldstein RS, Vanfleteren LEGW, Kenn K, Nici L, Janssen DJA, Casaburi R, Shioya T, Garvey C, Carlin BW, ZuWallack RL, Steiner M, Wouters EFM, Puhan MA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701312. doi: 10.1183/13993003.01312-2017. Print 2018 Jan. No abstract available.

PMID:
29326328
10.

Long-Term Oxygen Therapy: The Three Big Questions.

Casaburi R.

Ann Am Thorac Soc. 2018 Jan;15(1):14-15. doi: 10.1513/AnnalsATS.201709-715ED. No abstract available.

PMID:
29286852
11.

Chest computed tomography-derived low fat-free mass index and mortality in COPD.

McDonald MN, Diaz AA, Rutten E, Lutz SM, Harmouche R, San Jose Estepar R, Kinney G, Hokanson JE, Gower BA, Wouters EFM, Rennard SI, Hersh CP, Casaburi R, Dransfield MT, Silverman EK, Washko GR.

Eur Respir J. 2017 Dec 14;50(6). pii: 1701134. doi: 10.1183/13993003.01134-2017. Print 2017 Dec.

PMID:
29242259
12.

The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned.

Yusen RD, Criner GJ, Sternberg AL, Au DH, Fuhlbrigge AL, Albert RK, Casaburi R, Stoller JK, Harrington KF, Cooper JAD Jr, Diaz P, Gay S, Kanner R, MacIntyre N, Martinez FJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Tonascia J, Wise R, Bailey WC; LOTT Research Group * ; LOTT Research Group.

Ann Am Thorac Soc. 2018 Jan;15(1):89-101. doi: 10.1513/AnnalsATS.201705-374SD.

PMID:
29087741
13.

Simultaneous LC-MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF.

Thakare R, Chhonker YS, Gautam N, Nelson A, Casaburi R, Criner G, Dransfield MT, Make B, Schmid KK, Rennard SI, Alnouti Y.

Biomed Chromatogr. 2018 Mar;32(3). doi: 10.1002/bmc.4102. Epub 2017 Oct 17.

14.

Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts.

Bowler RP, Hansel NN, Jacobson S, Graham Barr R, Make BJ, Han MK, O'Neal WK, Oelsner EC, Casaburi R, Barjaktarevic I, Cooper C, Foreman M, Wise RA, DeMeo DL, Silverman EK, Bailey W, Harrington KF, Woodruff PG, Drummond MB; for COPDGene and SPIROMICS Investigators.

J Gen Intern Med. 2017 Dec;32(12):1315-1322. doi: 10.1007/s11606-017-4150-7. Epub 2017 Sep 7.

PMID:
28884423
15.

Spirometry, Static Lung Volumes, and Diffusing Capacity.

Vaz Fragoso CA, Cain HC, Casaburi R, Lee PJ, Iannone L, Leo-Summers LS, Van Ness PH.

Respir Care. 2017 Sep;62(9):1137-1147. doi: 10.4187/respcare.05515. Epub 2017 Jul 11.

PMID:
28698266
16.

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).

Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield M, Han MK, Make B, Marchetti N, Martinez F, Lazarus S, Niewoehner D, Scanlon PD, Sciurba F, Scharf S, Reed RM, Washko G, Woodruff P, McEvoy C, Aaron S, Sin D, Criner GJ; NIH COPD Clinical Research Network and the Canadian Institutes of Health Research.

Respir Res. 2017 Jun 19;18(1):124. doi: 10.1186/s12931-017-0609-7.

17.

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.

O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F.

Eur Respir J. 2017 Apr 19;49(4). pii: 1601348. doi: 10.1183/13993003.01348-2016. Print 2017 Apr.

18.

Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1.

McDonald MN, Won S, Mattheisen M, Castaldi PJ, Cho MH, Rutten E, Hardin M, Yip WK, Rennard SI, Lomas DA, Wouters EFM, Agusti A, Casaburi R, Lange CP, O'Connor G, Hersh CP, Silverman EK.

J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):428-436. doi: 10.1002/jcsm.12171. Epub 2017 Jan 2.

19.

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study.

Wells JM, Estepar RS, McDonald MN, Bhatt SP, Diaz AA, Bailey WC, Jacobson FL, Dransfield MT, Washko GR, Make BJ, Casaburi R, van Beek EJ, Hoffman EA, Sciurba FC, Crapo JD, Silverman EK, Hersh CP; COPDGene Investigators.

BMC Pulm Med. 2016 Dec 1;16(1):169.

20.

Relation of concavity in the expiratory flow-volume loop to dynamic hyperinflation during exercise in COPD.

Varga J, Casaburi R, Ma S, Hecht A, Hsia D, Somfay A, Porszasz J.

Respir Physiol Neurobiol. 2016 Dec;234:79-84. doi: 10.1016/j.resp.2016.08.005. Epub 2016 Aug 26.

PMID:
27575552
21.

Exercise, ageing and the lung.

Roman MA, Rossiter HB, Casaburi R.

Eur Respir J. 2016 Nov;48(5):1471-1486. doi: 10.1183/13993003.00347-2016. Epub 2016 Oct 6. Review.

22.

A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.

Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA Jr, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W.

N Engl J Med. 2016 Oct 27;375(17):1617-1627.

23.

Reproducibility of NIRS assessment of muscle oxidative capacity in smokers with and without COPD.

Adami A, Cao R, Porszasz J, Casaburi R, Rossiter HB.

Respir Physiol Neurobiol. 2017 Jan;235:18-26. doi: 10.1016/j.resp.2016.09.008. Epub 2016 Sep 19.

24.

Skeletal muscle power and fatigue at the tolerable limit of ramp-incremental exercise in COPD.

Cannon DT, Coelho AC, Cao R, Cheng A, Porszasz J, Casaburi R, Rossiter HB.

J Appl Physiol (1985). 2016 Dec 1;121(6):1365-1373. doi: 10.1152/japplphysiol.00660.2016. Epub 2016 Sep 22.

25.

Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.

Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, Basta PV, Bleecker ER, Beaty T, Casaburi R, Castaldi P, Cho MH, Comellas A, Crapo JD, Criner G, Demeo D, Christenson SA, Couper DJ, Curtis JL, Doerschuk CM, Freeman CM, Gouskova NA, Han MK, Hanania NA, Hansel NN, Hersh CP, Hoffman EA, Kaner RJ, Kanner RE, Kleerup EC, Lutz S, Martinez FJ, Meyers DA, Peters SP, Regan EA, Rennard SI, Scholand MB, Silverman EK, Woodruff PG, O'Neal WK, Bowler RP; SPIROMICS Research Group; COPDGene Investigators.

PLoS Genet. 2016 Aug 17;12(8):e1006011. doi: 10.1371/journal.pgen.1006011. eCollection 2016 Aug.

26.

A Novel Spirometric Measure Identifies Mild COPD Unidentified by Standard Criteria.

Dilektasli AG, Porszasz J, Casaburi R, Stringer WW, Bhatt SP, Pak Y, Rossiter HB, Washko G, Castaldi PJ, Estepar RSJ, Hansen JE; COPDGene investigators.

Chest. 2016 Nov;150(5):1080-1090. doi: 10.1016/j.chest.2016.06.047. Epub 2016 Jul 22.

27.

The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium.

Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, Tal-Singer R, Kawata A, Merrill D, Rennard S; COPD Biomarker Qualification Consortium.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1483-1493.

28.

Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease.

Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, Boriek AM, Casaburi R, Criner GJ, Diaz AA, Dransfield MT, Curran-Everett D, Galbán CJ, Hoffman EA, Hogg JC, Kazerooni EA, Kim V, Kinney GL, Lagstein A, Lynch DA, Make BJ, Martinez FJ, Ramsdell JW, Reddy R, Ross BD, Rossiter HB, Steiner RM, Strand MJ, van Beek EJ, Wan ES, Washko GR, Wells JM, Wendt CH, Wise RA, Silverman EK, Crapo JD, Bowler RP, Han MK; COPDGene Investigators.

Am J Respir Crit Care Med. 2016 Jul 15;194(2):178-84. doi: 10.1164/rccm.201511-2219OC.

29.

Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement.

Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, O'Donnell DE, Onorati P, Porszasz J, Rabinovich R, Rossiter HB, Singh S, Troosters T, Ward S.

Eur Respir J. 2016 Feb;47(2):429-60. doi: 10.1183/13993003.00745-2015. Epub 2016 Jan 21. Review.

30.

Biological quality control for cardiopulmonary exercise testing in multicenter clinical trials.

Porszasz J, Blonshine S, Cao R, Paden HA, Casaburi R, Rossiter HB.

BMC Pulm Med. 2016 Jan 16;16:13. doi: 10.1186/s12890-016-0174-8.

31.

Pulmonary Rehabilitation: Improvement with Movement.

Rajagopal A, Casaburi R.

Chronic Obstr Pulm Dis. 2016 Jan 15;3(1):479-484. doi: 10.15326/jcopdf.3.1.2015.0169.

32.

A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry.

Lutz SM, Cho MH, Young K, Hersh CP, Castaldi PJ, McDonald ML, Regan E, Mattheisen M, DeMeo DL, Parker M, Foreman M, Make BJ, Jensen RL, Casaburi R, Lomas DA, Bhatt SP, Bakke P, Gulsvik A, Crapo JD, Beaty TH, Laird NM, Lange C, Hokanson JE, Silverman EK; ECLIPSE Investigators; COPDGene Investigators.

BMC Genet. 2015 Dec 3;16:138. doi: 10.1186/s12863-015-0299-4.

33.

An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation.

Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, Spruit MA, Masefield S, Casaburi R, Clini EM, Crouch R, Garcia-Aymerich J, Garvey C, Goldstein RS, Hill K, Morgan M, Nici L, Pitta F, Ries AL, Singh SJ, Troosters T, Wijkstra PJ, Yawn BP, ZuWallack RL; ATS/ERS Task Force on Policy in Pulmonary Rehabilitation.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1373-86. doi: 10.1164/rccm.201510-1966ST.

PMID:
26623686
34.

Effect of Megestrol Acetate and Testosterone on Body Composition and Hormonal Responses in COPD Cachexia.

Casaburi R, Nakata J, Bistrong L, Torres E, Rambod M, Porszasz J.

Chronic Obstr Pulm Dis. 2015 Nov 9;3(1):389-397. doi: 10.15326/jcopdf.3.1.2015.0128.

35.

Phenotype of Spirometric Impairment in an Aging Population.

Vaz Fragoso CA, McAvay G, Van Ness PH, Casaburi R, Jensen RL, MacIntyre N, Yaggi HK, Gill TM, Concato J.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):727-35. doi: 10.1164/rccm.201508-1603OC.

36.

Patient Involvement in the Design of a Patient-Centered Clinical Trial to Promote Adherence to Supplemental Oxygen Therapy in COPD.

Holm KE, Casaburi R, Cerreta S, Gussin HA, Husbands J, Porszasz J, Prieto-Centurion V, Sandhaus RA, Sullivan JL, Walsh LJ, Krishnan JA.

Patient. 2016 Jun;9(3):271-9. doi: 10.1007/s40271-015-0150-z.

PMID:
26521057
37.

Effect of endurance and/or strength training on muscle fiber size, oxidative capacity, and capillarity in hemodialysis patients.

Lewis MI, Fournier M, Wang H, Storer TW, Casaburi R, Kopple JD.

J Appl Physiol (1985). 2015 Oct 15;119(8):865-71. doi: 10.1152/japplphysiol.01084.2014. Epub 2015 Jul 16.

38.

Phenotype of normal spirometry in an aging population.

Vaz Fragoso CA, McAvay G, Van Ness PH, Casaburi R, Jensen RL, MacIntyre N, Gill TM, Yaggi HK, Concato J.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):817-25. doi: 10.1164/rccm.201503-0463OC.

39.

Clinical and Radiologic Disease in Smokers With Normal Spirometry.

Regan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JH, Grenier PA, Kauczor HU, Bailey WC, DeMeo DL, Casaburi RH, Friedman P, Van Beek EJ, Hokanson JE, Bowler RP, Beaty TH, Washko GR, Han MK, Kim V, Kim SS, Yagihashi K, Washington L, McEvoy CE, Tanner C, Mannino DM, Make BJ, Silverman EK, Crapo JD; Genetic Epidemiology of COPD (COPDGene) Investigators.

JAMA Intern Med. 2015 Sep;175(9):1539-49. doi: 10.1001/jamainternmed.2015.2735. Erratum in: JAMA Intern Med. 2015 Sep;175(9):1588.

40.

Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease.

Gagnon P, Casaburi R, Saey D, Porszasz J, Provencher S, Milot J, Bourbeau J, O'Donnell DE, Maltais F.

PLoS One. 2015 Apr 23;10(4):e0123626. doi: 10.1371/journal.pone.0123626. eCollection 2015.

41.

Exercise limitation in chronic obstructive pulmonary disease. The O'Donnell threshold.

Casaburi R, Rennard SI.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):873-5. doi: 10.1164/rccm.201501-0084ED. No abstract available.

PMID:
25876202
42.

Re-Defining Lower Limit of Normal for FEV1/FEV6, FEV1/FVC, FEV3/FEV6 and FEV3/FVC to Improve Detection of Airway Obstruction.

Hansen JE, Porszasz J, Casaburi R, Stringer WW.

Chronic Obstr Pulm Dis. 2015 Mar 10;2(2):94-102. doi: 10.15326/jcopdf.2.2.2014.0144.

43.

Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.

Putcha N, Han MK, Martinez CH, Foreman MG, Anzueto AR, Casaburi R, Cho MH, Hanania NA, Hersh CP, Kinney GL, Make BJ, Steiner RM, Lutz SM, Thomashow BM, Williams AA, Bhatt SP, Beaty TH, Bowler RP, Ramsdell JW, Curtis JL, Everett D, Hokanson JE, Lynch DA, Sutherland ER, Silverman EK, Crapo JD, Wise RA, Regan EA, Hansel NN; the COPDGene® Investigators.

Chronic Obstr Pulm Dis. 2014;1(1):105-114.

44.

Instantaneous quantification of skeletal muscle activation, power production, and fatigue during cycle ergometry.

Coelho AC, Cannon DT, Cao R, Porszasz J, Casaburi R, Knorst MM, Rossiter HB.

J Appl Physiol (1985). 2015 Mar 1;118(5):646-54. doi: 10.1152/japplphysiol.00948.2014. Epub 2014 Dec 24.

45.

An official European Respiratory Society statement on physical activity in COPD.

Watz H, Pitta F, Rochester CL, Garcia-Aymerich J, ZuWallack R, Troosters T, Vaes AW, Puhan MA, Jehn M, Polkey MI, Vogiatzis I, Clini EM, Toth M, Gimeno-Santos E, Waschki B, Esteban C, Hayot M, Casaburi R, Porszasz J, McAuley E, Singh SJ, Langer D, Wouters EF, Magnussen H, Spruit MA.

Eur Respir J. 2014 Dec;44(6):1521-37. doi: 10.1183/09031936.00046814. Epub 2014 Oct 30.

46.

Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.

Casaburi R, Maltais F, Porszasz J, Albers F, Deng Q, Iqbal A, Paden HA, O'Donnell DE; 205.440 Investigators.

Ann Am Thorac Soc. 2014 Nov;11(9):1351-61. doi: 10.1513/AnnalsATS.201404-174OC.

PMID:
25289942
47.

Improving early-stage diagnosis and management of COPD in primary care.

Casaburi R, Duvall K.

Postgrad Med. 2014 Jul;126(4):141-54. doi: 10.3810/pgm.2014.07.2792. Review.

PMID:
25141252
48.

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.

Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, Make B, Marchetti N, Martinez FJ, Niewoehner DE, Scanlon PD, Sciurba FC, Scharf SM, Sin DD, Voelker H, Washko GR, Woodruff PG, Lazarus SC; COPD Clinical Research Network; Canadian Institutes of Health Research.

N Engl J Med. 2014 Jun 5;370(23):2201-10. doi: 10.1056/NEJMoa1403086. Epub 2014 May 18.

49.

Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease.

McDonald ML, Cho MH, Sørheim IC, Lutz SM, Castaldi PJ, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard SI, Wouters EF, Bakke P, Tal-Singer R, Miller BE, Gulsvik A, Casaburi R, Wells JM, Regan EA, Make BJ, Hokanson JE, Lange C, Crapo JD, Beaty TH, Silverman EK, Hersh CP; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints and COPDGene Investigators.

Am J Respir Cell Mol Biol. 2014 Nov;51(5):678-87. doi: 10.1165/rcmb.2014-0135OC.

50.

The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial.

O'Donnell DE, Maltais F, Porszasz J, Webb KA, Albers FC, Deng Q, Iqbal A, Paden HA, Casaburi R; 205.440 investigators.

PLoS One. 2014 May 1;9(5):e96574. doi: 10.1371/journal.pone.0096574. eCollection 2014.

Supplemental Content

Loading ...
Support Center